Monoclonal gammopathy

The International Myeloma Foundation and Black Swan Research Initiative® Announce the Release of New iStopMM Cohort Study: A Multivariable Prediction Model for Bone Marrow Sampling on Individuals with MGUS

Retrieved on: 
Thursday, April 11, 2024
Immunoglobulin G, International Myeloma Foundation, University, Bone marrow, Mayo Clinic, Randomized controlled trial, Overfitting, Multiple myeloma, Annals of Internal Medicine, MGUS, Probability, Risk, Monoclonal gammopathy, Immunoglobulin M, Research, Calibration, Immunoglobulin A, IQR, European Research Council, Clinical, IMF, SMM, B cell, Black swan, Diagnosis, Clutch (eggs), Internal medicine, Smouldering, Lymphoproliferative disorders, BSRI, Ageing, Medical device

IMF Chief Scientific Officer and co-author of the iStopMM cohort study Dr. Brian G.M.

Key Points: 
  • IMF Chief Scientific Officer and co-author of the iStopMM cohort study Dr. Brian G.M.
  • Groups 2 and 3 were evaluated at the study clinic for initial assessment and follow-up, including bone marrow sampling,” according to the study.
  • However, [this] model requires validation in other populations.”
    To know the full details of the iStopMM cohort study , view it online.
  • This research was funded by the International Myeloma Foundation and the European Research Council.

Four Oral Presentations from the International Myeloma Foundation-Supported iStopMM Study to Take Center Stage at 2021 ASH Annual Meeting

Retrieved on: 
Thursday, November 4, 2021
Congress Center, Research, Prevalence, Quality of life, Diagnosis, University, Clinical study design, India Infoline, International Myeloma Foundation, Kidney, Black swan, IMF, SMM, Patient, Multiple myeloma, Foundation, Abstract, ASH, Risk, Board, Georgia World Congress Center, COVID-19, Education, Monoclonal gammopathy, Monoclonal gammopathy of undetermined significance, Pharmaceutical industry, Communications satellite

"It confirms that iStopMM really has the potential to profoundly impact the field of multiple myeloma."

Key Points: 
  • "It confirms that iStopMM really has the potential to profoundly impact the field of multiple myeloma."
  • Oral presentations at ASH 2021 from the iStopMM study:
    Screening for Monoclonal Gammopathy of Undetermined Significance: A Population-Based Randomized Clinical Trial.
  • First Results from the Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) Study (Abstract #156, Session: 652.
  • Prevalence of Smoldering Multiple Myeloma: Results from the Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) Study (Abstract #151, Session: 652.

New CAP Guideline Improves Diagnoses of Patients with Monoclonal Gammopathies

Retrieved on: 
Tuesday, August 10, 2021
General Health, Health, Science, Research, Oncology, American Society for Clinical Pathology, Pathology, International Myeloma Foundation, FAQ, Patient, Association, MGS, Diagnosis, ASCP, Guideline, AACC, Monoclonal gammopathy, College, Serum protein electrophoresis, American Association for Clinical Chemistry, Software, CAP, Marie Cassidy, READ, American Association, ASH, Society, SPEP, MGUS, Laboratory, Archives of Pathology & Laboratory Medicine, Medical laboratory, Medical device, Medicine

The College of American Pathologists (CAP) new evidence-based clinical practice guideline, Laboratory Detection and Initial Diagnosis of Monoclonal Gammopathies, establishes recommendations that pathologists and clinicians can implement to better manage testing and improve the accurate diagnoses of patients with monoclonal gammopathies (MGs).

Key Points: 
  • The College of American Pathologists (CAP) new evidence-based clinical practice guideline, Laboratory Detection and Initial Diagnosis of Monoclonal Gammopathies, establishes recommendations that pathologists and clinicians can implement to better manage testing and improve the accurate diagnoses of patients with monoclonal gammopathies (MGs).
  • The guideline was published August 4, 2021, as an early online release in Archives of Pathology & Laboratory Medicine.
  • MGs encompass a wide variety of patient conditions that can range in severity from the asymptomatic Monoclonal Gammopathy of Undetermined Significance (MGUS) to the potentially life-threatening Multiple Myeloma.
  • To help the medical community implement the guideline, the CAP provides related resources, including a summary of recommendations, a teaching presentation, FAQs, and an algorithm, available at no cost on cap.org .